Dexcom announced the promotion of Jake Leach to CEO and to the Dexcom board of directors, effective January 1, 2026. Current CEO Kevin Sayer will continue to work closely with Leach during the transition period and will remain executive chairman of the board of directors at the point of transition.
“Today’s announcement of Jake’s transition to the role of chief executive officer reflects the board’s comprehensive succession planning and their confidence in Jake’s leadership throughout his tenure. We are confident that he is the right leader to build on Dexcom’s momentum and extend the company’s growth well into the future,” said Sayer in a statement.
“I am humbled and excited to transition into the CEO role at this critical time in Dexcom’s history,” said Leach in a statement. “I look forward to leading our incredible teams as we advance access to our technology to more people around the world, empowering better metabolic health for our customers and creating value for our stakeholders.”
Leach has helped steer the company’s biosensing platforms since the launch of its first commercial system. He served as executive vice president and chief technology officer from 2018 through 2022, transitioning to executive vice president and chief operating officer in late 2022. In May 2025, he was promoted to the expanded role of president and chief operating officer, assuming the additional responsibility of oversight for the company’s strategy and corporate development efforts.
